Prices, Pfizer and Moderna raise price of vaccines
https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-news-nhs-double-covid-vaccine-uk-cases-isolation/
European Union supply contracts
One Pfizer shot now 19.50 euros (£16.65)
Up from 15.50 euros previously
One Moderna dose £18.30
Up from about £16 in the first procurement deal
Joint Committee on Vaccination and Immunisation
https://www.gov.uk/government/news/statement-on-offering-covid-19-vaccination-to-young-people
https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years
https://www.bbc.co.uk/news/uk-58091693
16 and 17-year-olds in the UK will be offered a first dose soon
1.4 million will be eligible
Prof Jonathan Van-Tam
We have the supply and I’m expecting this to start in a very short number of weeks indeed
There is no time to waste in getting on with this
I want us to proceed as fast as is practically possible
Pfizer-BioNTech only
Routinely vaccinating children over 12
United States since May
France Italy, Brazil, Japan, Israel, Hong Kong
Vaccine safety
https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021
The Pfizer-BioNTech BNT162b2 vaccine is administered via intramuscular injection, usually in the upper arm.
Most frequent reactions aged 12 to 17 years
Injection site pain, fever and headache
Generally mild, self-limiting and short-lived, (1 to 2 days)
FDA data on pericarditis and myocarditis
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021
Onset of symptoms within a few days after vaccination
Particularly following the second dose
Chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart
Pfizer-BioNTech BNT162b2 and Moderna mRNA- 1273
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions
These extremely rare adverse reactions have been more frequent shortly after the second dose, and in younger individuals and males
60 cases per million
https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm
6 or 7 times more common after the second dose
1 in 16,666
1.4 million will be eligible = 84 cases
The mechanism of action underlying these rare events is not currently known
Israel and the United States have reported most of the cases
Milder phenotype
Vast majority recovering swiftly from the acute episode, compared to more typical cases of myocarditis
Benefits of vaccination
Secondary school-aged children in England (early July)
Antibody positive is approximately 40%
England, February 2020 and March 2021
61 deaths after testing positive
https://www.medrxiv.org/content/10.1101/2021.07.07.21259779v1
22 from acute infection and three from PIMS
mortality rate of 2/million for the 12,023,568 CYP living in England
Survival rate after testing positive = 99·995%
Second wave, hospitalisation rate, 100 to 400 per million
Severe neuro-disabilities, Down’s Syndrome, underlying conditions resulting in immunosuppression, severe learning disabilities
March 2020 TO July 2020
449 cases of PIMS in persons under 16 years
44% were admitted to paediatric intensive care
Overall case fatality ratio was 1.1%
Existing studies suggest that longer term (more than 8 weeks) symptoms following SARS-CoV2 infection occur in about 1% to 10% of persons after COVID-19
Avoiding school and class-based measures
Benefits to adult is highly uncertain
UK, cases up a bit today
https://coronavirus.data.gov.uk
Includes lateral flow tests
https://ourworldindata.org/coronavirus
Tuesday, 4th August, + 29,312
Monday 3rd August, 21,691
Source